Dikora Bulk Drug Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.46 Cr
- Revenue Growth 2721615.13%
- Profit Growth 13.76%
- Ebitda 271.30%
- Net Worth -88.51%
- Total Assets 67.94%
About Dikora Bulk Drug
Dikora Bulk Drug Private Limited (DBDPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 28 December 2017 (Seven years and one month 12 days old ). Its registered office is in Jalgaon, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹6.46 Cr.
Dineshkumar Patel, Yogesh Patel, Pratik Patel, and Two other members serve as directors at the Company.
Company Details
-
Location
Jalgaon, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100MH2017PTC303432
-
Company No.
303432
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Dec 2017
-
Date of AGM
16 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Dikora Bulk Drug?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dineshkumar Patel
|
Director | 28-Dec-2017 | Current |
|
Yogesh Patel
|
Director | 28-Dec-2017 | Current |
|
Pratik Patel
|
Director | 28-Dec-2017 | Current |
|
Rohit Patel
|
Director | 28-Dec-2017 | Current |
|
Komal Patil
|
Director | 28-Dec-2017 | Current |
Financial Performance of Dikora Bulk Drug.
Dikora Bulk Drug Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 2721615.13% increase. The company also saw a substantial improvement in profitability, with a 13.76% increase in profit. The company's net worth observed a substantial decline by a decrease of 88.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dikora Bulk Drug?
In 2020, Dikora Bulk Drug had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹6.46 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 3.88 Cr
- Hdfc Bank Limited : 2.58 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Oct 2024 | Hdfc Bank Limited | ₹2.58 Cr | Open |
| 04 Dec 2018 | State Bank Of India | ₹3.88 Cr | Open |
How Many Employees Work at Dikora Bulk Drug?
Unlock and access historical data on people associated with Dikora Bulk Drug, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dikora Bulk Drug, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dikora Bulk Drug's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
